PD-1-CTLA-4 is once again creating a survival miracle: breaking the 15-year stalemate in thoracic mesothelioma without new drugs.

Following traditional surgical treatments, radiotherapy and chemotherapy, tumor immunotherapy shines clinically like a pearl in the crown.
it overcomes systemic side effects such as multidring resistance to chemotherapy drugs and takes a way to stimulate the body's own strength (immune system T-cells) to fight tumors.
, broad immunotherapy includes immunosuppressants, immunocell therapy, lysovirus, cancer vaccines, and immune system regulators.
, immuno-checkpoint inhibitors have been the focus of academic attention since they were discovered.
, Navuliyu monoanti (PD-1) and Ipimu monoanti (CTLA-4) have been approved for treatment of hepatocellular carcinoma, EGFR/ALK negative metastatic NSCLC, etc.
Recently, Checkmate-743 research results announced that The Navuliyu mono-Ipimu mono-resistance once again created a miracle of survival, can significantly improve the total survival of patients with previously untreated, non-removable malignant thoracic mesothelioma (OS), but also broke the deadlock of 15 years of no new drugs for thoracic mesothelioma.
malignant thoracic mesothelioma (MPM) is a rare and highly invasive primary thoracic tumor that is highly correlevant to asbestos exposure.
the clinical performance of MPM is not typical, the prognosis of different pathological sub-types is poor, and the treatment means are limited.
in patients with previously untreated advanced or metastasis malignant thoracic mesothelioma, the neutral OS was less than 1 year and the five-year survival rate was about 10%.
MPM treatment program has been dominated by chemotherapy.
2004, the effect of platinum-type combined anti-metabolic drugs was found to be improved, but the effect was still unsatisfactory.
follow-up finding that the platinum mitigation rate of the Pemese combined card reached 43%, which is not a small breakthrough.
Pyethon co-platinum class has become the standard treatment of MPM, has been used to this day, is also the NCCN guidelines recommended the preferred solution.
but although the mitigation rate has broken through, the survival period is not ideal.
until immunotherapy appears, there are more opportunities for the treatment of thoracic mesothelioma.
the results of the Navuliyu monoanti (PD-1) joint Ipimu monoanti (CTLA-4) were released, bringing a new dawn to MPM patients.
CheckMate-743 is an open-label, multi-center, randomized, Phase III clinical study designed to assess the therapeutic effectiveness of Narvulyu monoantigen monoantigen for previously untreated patients with malignant MPM (n-605) compared to standard chemotherapy (Pemetroser combined cisplatin or carptonin).
In this clinical study, 303 patients were treated with navuliyu monoanti (3mg/kg) every two weeks and Ipimu monoanti (1mg/kg) every six weeks for a maximum duration of 24 months, or until the disease progressed or be impatient.
302 patients were treated with cisplatin (75 mg/m2) or carptin (AUC 5) in a 21-day cycle, which lasted six cycles until the disease progressed or beedible.
end point of the trial was the total lifetime (OS) of all randomized grouped patients, and the key secondary endpoints included objective mitigation rate (ORR), disease control rate (DCR), and progress-free lifetime (PFS).
endpoints include safety, pharmacogenetics, immunogenicity, and patient reporting outcomes.
the results of the study all patients were followed for at least 2 years, with a total survival rate of 40.8% in the two-year immunology group and only 27.0% in the chemotherapy group.
18.1 months in the two-drug immunotherapy group and 14.1 months in the chemotherapy group (HR 0.74, 96.6% CI 0.60-0.91), the statistical difference was significant.
? All pathological subtypes benefit, and the most obvious histological type of non-epithelat benefit is the recognized prognosis factor for malignant thoracic mesothelioma, rather than epitheline type, which usually has a worse prognosis.
In this study, the survival of patients with non-epithelial and epithelial thoracic mesotheliomas treated with Navuliyu monoantigen monotherapy was improved, with greater benefit observed in the subgroups of non-epithelial patients.
In the biimmune combination therapy group, the mesothentic OS in the upper and non-corted patients was 18.7 months and 18.1 months, respectively, while in the chemotherapy group, the mesothos in the corresponding patients were 16.5 months and 8.8 months respectively (upper-skin subgroup HR: 0.86 (95% CI: 0.69, 1.08? Non-skin subgroup HR: 0.46 (95% CI: 0.31, 0.68) ).
strength to overcome the difficult to cure sub-type treatment gaps.
? The safety of the double-exemption program was similar to that of chemotherapy, with 30.3% of patients in the patient's well-to-do double immunotherapy group suffering from level 3-4 adverse events, of which 15% received treatment with suspension, while 32.0% of patients in the chemotherapy group experienced level 3-4 adverse events, of which 7.4% stopped.
Navuliyu monoantigen is a unique combination of two immuno-checkpoint inhibitors that target two different checkpoints (PD-1 and CTLA-4) to help destroy tumor cells, both of which have potential synergies: Ibmu monoantigen promotes the activation and proliferation of T cells, while Navuliyu monoantigen helps existing T cells identify tumor cells.
T cells activated by Ipimu monoantigen can also differentiate into memory T cells, helping to achieve a long-term anti-tumor immune response.
CheckMate-743 is the first and only Phase III clinical trial to demonstrate that first-line immunotherapy can improve survival benefits in patients with malignant thoracic mesothelioma.
based on this positive result, Navuliyu monoantigen has shown clinical benefits in six different tumor species, including a sustained and significant survival benefit that is superior to chemotherapy for two of these breast tumors.
the results of the study is another survival miracle created by the dual-free joint program.
()